As patient portals become increasingly central to chronic disease management, new research presented at CMSC 2025 offers insights into how people living with multiple sclerosis (MS) use these tools—and how their adoption may intersect with...
As patient portals become increasingly central to chronic disease management, new research presented at CMSC 2025 offers insights into how people living with multiple sclerosis (MS) use these tools—and how their adoption may intersect with...
At CMSC 2025, researchers presented 11-year follow-up data confirming the long-term efficacy and safety of ocrelizumab (OCR) in people with multiple sclerosis (pwMS), including both relapsing (pwRMS) and primary progressive (pwPPMS) forms of...
At CMSC 2025, researchers presented 11-year follow-up data confirming the long-term efficacy and safety of ocrelizumab (OCR) in people with multiple sclerosis (pwMS), including both relapsing (pwRMS) and primary progressive (pwPPMS) forms of...
A real-world study found that cladribine tablets significantly reduce relapse rates and deliver high patient satisfaction in patients with relapsing multiple sclerosis switching from injectable therapies.
A real-world study found that cladribine tablets significantly reduce relapse rates and deliver high patient satisfaction in patients with relapsing multiple sclerosis switching from injectable therapies.
Multiple Sclerosis Disease Activity (MSDA) scores aligned with real-world multiple sclerosis scenarios, suggesting the test may help monitor disease activity and guide care between standard visits.
Multiple Sclerosis Disease Activity (MSDA) scores aligned with real-world multiple sclerosis scenarios, suggesting the test may help monitor disease activity and guide care between standard visits.
New research presented at CMSC 2025 questions the long-term benefits of disease-modifying therapies (DMTs) in multiple sclerosis (MS), suggesting that these therapies may not improve mobility outcomes and could be associated with higher...
New research presented at CMSC 2025 questions the long-term benefits of disease-modifying therapies (DMTs) in multiple sclerosis (MS), suggesting that these therapies may not improve mobility outcomes and could be associated with higher...
A retrospective cohort study presented at the 2025 ACTRIMS Forum challenges conventional assumptions regarding disease-modifying therapies (DMTs) in multiple sclerosis (MS). While DMTs are designed to reduce relapse rates and MRI activity,...
A retrospective cohort study presented at the 2025 ACTRIMS Forum challenges conventional assumptions regarding disease-modifying therapies (DMTs) in multiple sclerosis (MS). While DMTs are designed to reduce relapse rates and MRI activity,...
Treatment with ozanimod in patients with early relapsing multiple sclerosis (MS) showed promising results in preserving brain volume over 1 year, potentially slowing down the accelerated brain volume loss seen in patients with MS.
Treatment with ozanimod in patients with early relapsing multiple sclerosis (MS) showed promising results in preserving brain volume over 1 year, potentially slowing down the accelerated brain volume loss seen in patients with MS.
A study on the effects of a modified Atkins diet in patients with multiple sclerosis reveals significant changes in immune cell metabolism and anti-inflammatory responses, suggesting the potential for dietary interventions in multiple...
A study on the effects of a modified Atkins diet in patients with multiple sclerosis reveals significant changes in immune cell metabolism and anti-inflammatory responses, suggesting the potential for dietary interventions in multiple...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
